1. 1761PRisk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance. (23rd October 2018) Authors: Thein, K Z; Sultan, A; Zaw, M H; Han, M M; Yu, N H; Igid, H P; Jones, C; D'Cunha, N; Awasthi, S; Hardwicke, F Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗